Second Sight Medical Products (NASDAQ:EYES) Upgraded to Hold at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Second Sight Medical Products (NASDAQ:EYES) from a sell rating to a hold rating in a report published on Tuesday morning, ValuEngine reports.

Separately, Zacks Investment Research raised Second Sight Medical Products from a hold rating to a buy rating and set a $1.00 price target on the stock in a research note on Wednesday, November 20th.

Shares of NASDAQ:EYES opened at $0.86 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.83 and a quick ratio of 2.66. The business’s 50-day moving average is $0.83 and its 200-day moving average is $0.81. Second Sight Medical Products has a 1 year low of $0.63 and a 1 year high of $1.20.

Second Sight Medical Products (NASDAQ:EYES) last announced its earnings results on Thursday, November 14th. The medical device company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). Second Sight Medical Products had a negative return on equity of 201.34% and a negative net margin of 743.86%. The company had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.94 million. Equities analysts anticipate that Second Sight Medical Products will post -0.29 EPS for the current fiscal year.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.

See Also: Why do commodities matter?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.